Valeant Pharmaceuticals Fair Value Of $43: Too High?Tuesday, August 9 is a milestone day for Valeant Pharmaceuticals (VRX). The company reports quarterly results before the market opens. With its stock Flat-lined at $22 (closing at $21.96 on Aug 5), it is nearly below the average analyst target price of around $43. At 7.7x EV / EBITDA but an ROIC of just 1.8 percent, Valeant’s future value depends on.......Continue reading on journal.B+L:Earnings roundup:This week’s earnings release will have mostly discretionary companies reporting results. Tyson, Hertz, Shake Shack (SHAK), Kohls (KSS), Nordstrom, Coach (COH), and Macy’s (M). In the last round of reports from retailers, stocks fell because the companies admitted consumers were shopping online. They visited malls less often. Endo Pharmaceuticals’ (ENDP) quarterly report is notable. It relies....join group for free and read more here.Previously: BlackBerry DTEK50Etsy may soar to the moonBears weigh on Valeant $BBRY, BlackBerry Limited / 60